iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) Sets New 52-Week Low – Should You Sell?

iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $60.12 and last traded at $61.71, with a volume of 104451 shares. The stock had previously closed at $63.43.

iShares U.S. Pharmaceuticals ETF Stock Performance

The stock has a market cap of $550.18 million, a PE ratio of 25.04 and a beta of 0.63. The company’s 50-day moving average price is $70.04 and its 200 day moving average price is $69.02.

Institutional Trading of iShares U.S. Pharmaceuticals ETF

Several institutional investors and hedge funds have recently bought and sold shares of IHE. Atala Financial Inc purchased a new position in iShares U.S. Pharmaceuticals ETF during the fourth quarter worth about $25,000. Union Bancaire Privee UBP SA acquired a new stake in iShares U.S. Pharmaceuticals ETF in the 4th quarter valued at approximately $42,000. Capital Analysts LLC increased its holdings in iShares U.S. Pharmaceuticals ETF by 41.8% in the 4th quarter. Capital Analysts LLC now owns 1,575 shares of the company’s stock valued at $104,000 after purchasing an additional 464 shares during the last quarter. EP Wealth Advisors LLC acquired a new position in iShares U.S. Pharmaceuticals ETF during the third quarter worth $157,000. Finally, Comerica Bank lifted its stake in iShares U.S. Pharmaceuticals ETF by 23.1% during the fourth quarter. Comerica Bank now owns 2,466 shares of the company’s stock worth $162,000 after purchasing an additional 462 shares in the last quarter.

iShares U.S. Pharmaceuticals ETF Company Profile

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.